Our next #TeachingTuesday is brought to you by the University of Maryland's PGY-2 Cardiology Pharmacy Resident, Tiffany Gardner, PharmD! Be sure to check out her infographic on Antithrombotic Management after TAVR!

It's time for another #TeachingTuesday!! Check out this amazing infographic on Antithrombotic Management After TAVR created by the University of Maryland's PGY-2 Cardiology Pharmacy Resident, Tiffany Gardner, PharmD! 🫀

Among patients with suspected sepsis and no clear indication for antianaerobic coverage, administration of piperacillin-tazobactam was associated with higher mortality and increased duration of organ dysfunction compared with cefepime. ja.ma/3QKcBaS

Happy #WhatsNewWednesday! Check out the new 2024 lower extremity PAD guidelines released yesterday!

Our PGY-2 Cardiology Residents Dr. Tiffany Gardner and Dr. Katie Sandquist attended the American College of Cardiology Conference in Atlanta, GA and met up with our previous PGY-2 Cardiology Resident Dr. Aaron Adkisson! 🫀 Tiffany Gardner, PharmD Katie Sandquist Aaron B. Adkisson, PharmD, BCCP

The antibody that mediates the occurrence of VITT associated with adenoviral-based Covid-19 vaccines is nearly identical to the antibodies produced in response to natural adenoviral infection. Read the full correspondence: nej.md/3ygUva1

Happy #ThrowbackThursday! Tiffany Gardner, PharmD walks us through a 2002 NEJM trial that investigated aspirin use in CABG, which is now the gold standard after the surgery 💊

The Management of Cardiogenic Shock From Diagnosis to Devices: A Narrative Review Read more in the June issue of #journal_CHESTCritCare: hubs.la/Q02CT4rq0 #MedEd #JournalCHEST

The Management of Cardiogenic Shock From Diagnosis to Devices: A Narrative Review Read more in the latest issue of #journal_CHESTCritCare: hubs.la/Q02GjDjh0 #MedEd #JournalCHEST

It’s #WhatsNewWednesday! New guidance on managing kidney dysfunction in advanced heart failure--including patients with LVAD and HT. Check it out in Circulation👇 ahajournals.org/doi/abs/10.116…

#FamilialHypercholesterolemia is a genetic condition that affects millions of people worldwide, & the ACC is working to increase awareness in honor of #FHAwarenessDay. Learn more about the condition through the FH: Improving Detection to Accelerate Treatment online course &

🆕 New analysis from SEQUOIA-HCM presented at #HFSA2024 and published in JACC Journals shows treatment with aficamten in patients with oHCM was associated with broad clinical efficacy across multiple outcome domains. Read more on the findings + additional editorial commentary

Sacubitril/Valsartan in patients with HF & deterioration in eGFR to <30 with therapy. Continuation of ARNi was associated with persistent clinical benefit and no incremental risk. JACC Journals #JACCHF jacc.org/doi/10.1016/j.…

This updated guideline is intended to be a resource for clinicians to use to guide various prevention strategies for individuals with no history of stroke, and replaces the 2014 Guidelines for the Primary Prevention of Stroke.

From development to approval it’s finally come full circle

🚨 The ADA addresses safety concerns over compounded GLP-1 RA & GIP/GLP-1 RA medications amid rising demand & shortages. Guidance aims to ensure safe, effective care for people with #T2D & #Obesity. Learn more: bit.ly/3ZxNRrb ➡️ Check out the press release!

Mineralocorticoid Antagonism in Heart Failure: Established and Emerging Therapeutic Role Nonsteroidal MRAs show promise for HF due to superior specificity, potency, and tolerability jacc.org/doi/abs/10.101…

The EHRA Antiarrhythmic Drug Compendium is now published in full A practical, comprehensive resource for the safe and effective use of AADs in daily practice.

🆕 ACC Concise Clinical Guidance Consolidates Recommendations on Immunization as Part of CV Care Primary vaccine takeaways include: ✅ Influenza ✅ Pneumococcal ✅ #COVID19 ✅ RSV ✅ Shingles 📖 Read the journal scan for more: bit.ly/45Qig61 #cvPrev

FINAL REMINDER - Our next Journal Club presentation is TODAY Wednesday, August 27th at 2 PM EST / 1 PM CST! Join us as PGY2 Residents, Drs. Kayla Mitzel and Anna Piech present on the ATTR-ACT and ATTRibute-CM Trials! Please see list serve for the Teams link. See you soon!